Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.59 |
| ▸ | FEN1 | P39748 | 2/20 | 0.52 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.49 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.48 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.48 |
| ▸ | PTGER1 | P34995 | 4/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | USP2 | O75604 | 2/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | PPIA | P62937 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | DHFR | P00374 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | TTR | P02766 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16624212 | 0.87 | FFAR4 (0.62) | FFAR4MCL1SLC6A4SLC6A3PTGER1 | |
| SCHEMBL1958139 | 0.87 | FFAR4 (0.75) | FFAR4PTGER1NPC1L3MBTL1LMNA | |
| SCHEMBL17535871 | 0.85 | TDP1 (0.51) | FFAR4SLC6A4SLC6A3NPC1USP2 | |
| SCHEMBL16616176 | 0.83 | FFAR4 (0.52) | FFAR4PTGER1NPC1L3MBTL1TDP1 | |
| SCHEMBL1741575 | 0.81 | FFAR4 (0.67) | FFAR4MCL1NPC1L3MBTL1LMNA | |
| SCHEMBL9832985 | 0.81 | FEN1 (0.50) | FFAR4FEN1MCL1PTGER1NPC1 | |
| SCHEMBL7910894 | 0.80 | FFAR4 (0.65) | FFAR4L3MBTL1LMNAMAPTKMT2A | |
| SCHEMBL17040660 | 0.80 | FFAR4 (0.60) | FFAR4NPC1L3MBTL1LMNAMAPT | |
| SCHEMBL16616105 | 0.79 | FFAR4 (0.48) | FFAR4SLC6A4SLC6A3NPC1L3MBTL1 | |
| SCHEMBL16616086 | 0.78 | SLC6A4 (0.47) | FFAR4FEN1SLC6A4SLC6A3NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3063139-B1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2018-11-21 | — | — | EP | disclosed |
| EP-3055309-B1 | ANTAGONISTS OF SOMATOSTATIN RECEPTOR SUBTYPE 5 (SSTR5) | TAKEDA PHARMACEUTICALS CO (JP) | 2018-06-13 | — | — | EP | disclosed |
| US-9751878-B2 | Tetrahydronaphthyridine somatostatin receptor 5 antagonists | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-09-05 | — | — | US | disclosed |
| EP-2970331-B1 | SPIRO AZETIDINE ISOXAZOLE DERIVATIVES AND THEIR USE AS SSTR5 ANTAGONISTS | TAKEDA PHARMACEUTICALS CO (JP) | 2017-05-17 | — | — | EP | disclosed |
| US-9605000-B2 | Spiro azetidine isoxazole derivatives and their use as SSTR antagonists | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-03-28 | — | — | US | disclosed |
| EP-3063139-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2016-09-07 | — | — | EP | disclosed |
| US-20160237087-A1 | HETEROCYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-08-18 | — | — | US | disclosed |
| EP-3055309-A1 | ANTAGONISTS OF SOMATOSTATIN RECEPTOR SUBTYPE 5 (SSTR5) | Takeda Pharmaceutical Company Limited (JP) | 2016-08-17 | — | — | EP | disclosed |
| US-9353108-B2 | Tetrahydronaphthyridine somatostatin receptor 5 antagonists | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-05-31 | — | — | US | disclosed |
| US-20160060273-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-03-03 | — | — | US | disclosed |
| US-9120777-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-09-01 | — | — | US | disclosed |
| WO-2015064083-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-05-07 | — | — | WO | disclosed |
| US-20150119412-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-04-30 | — | — | US | disclosed |
| WO-2015052910-A1 | ANTAGONISTS OF SOMATOSTATIN RECEPTOR SUBTYPE 5 (SSTR5) | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-04-16 | — | — | WO | disclosed |
| US-20150099777-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150099777-A1 | HETEROCYCLIC COMPOUND | SSTR5, SSTR4, SSTR2 | FFAR4 359/4885FEN1 4835/4885MCL1 4200/4885 |
| US-20160060273-A1 | HETEROCYCLIC COMPOUND | SSTR5, SSTR1, SSTR2 | FFAR4 595/4885FEN1 4838/4885MCL1 917/4885 |
| US-20160237087-A1 | HETEROCYCLIC COMPOUNDS | SSTR5, SSTR4, SSTR2 | FFAR4 351/4885FEN1 4821/4885MCL1 4034/4885 |
| US-20150119412-A1 | HETEROCYCLIC COMPOUND | SSTR5, SSTR4, SSTR2 | FFAR4 384/4885FEN1 4820/4885MCL1 4065/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.